Antipsychotic Polypharmacy in Schizophrenia: Why Not?
J Clin Psychiatry
.
2020 Apr 28;81(3):19ac13118.
doi: 10.4088/JCP.19ac13118.
Authors
Daniel Guinart
1
2
3
,
Christoph U Correll
4
1
2
3
5
Affiliations
1
Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, USA.
2
Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
3
Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Manhasset, New York, USA.
4
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 500 Hofstra University, Hempstead, NY 11549. ccorrell@northwell.edu.
5
Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.
PMID:
32369690
DOI:
10.4088/JCP.19ac13118
No abstract available
MeSH terms
Antipsychotic Agents / administration & dosage
Antipsychotic Agents / therapeutic use*
Drug Therapy, Combination
Humans
Polypharmacy*
Schizophrenia / drug therapy*
Treatment Outcome
Substances
Antipsychotic Agents